Skip to main content
Equibles
NEUP logo

NEUP · Neuphoria Therapeutics Inc.

Track NEUP — free

Use NEUP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NEUP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.51 +0.12 (+3.54%)
Rebalance outlook locked
Market Cap
$18.34M
Shares
5.41M
Volume · Oct 21 5439 Avg daily vol (3M) 159.22K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.39 Open$3.37 Day$3.33–3.40 52W close$3.24–15.40 Avg vol 30d19K Short int20K · 0.4% float · 1.6d Short vol0% DataDec 2021–Oct 2026 Filing10-K · Sep 18

Up next

Latest filing: 10-K
filed Sep 18, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$13.45M
Trailing 12 months
Revenue growth YoY
-92.5%
Year over year
Operating margin
-1,401.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$19.87M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+214.8%
Year over year · more shares
Price change (1Y)
-78.0%
Trailing year
Short interest
0.4%
Latest settlement · 1.6 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −19%
below
Price vs 50-day avg −7%
below
RSI (14) 41
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −35%
trailing
YTD return −13%
this year
Relative strength −43%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+16% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.37% of float · ▼ -19.0% MoM · 1.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
22 holders — near 1-yr high, broad support
Squeeze score 41
elevated · 0–100
Fundamentals
Weak
Revenue growth −92%
Y/Y
EPS growth −1230%
Y/Y
Balance sheet $19.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 107%
annualized · 1-yr
Max drawdown −79%
past year
ATR 3.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−19% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
41 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+16% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.37% of float · ▼ -19.0% MoM · 1.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
22 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $3 · 1% Range high $15
vs 200-day avg -19% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NEUP
Neuphoria Therapeutics Inc.
this stock
$18.34M -12.6% -92.5% — 0.4%
VRTX
Vertex Pharmaceuticals Inc
 $131.39B +13.5% +46.2% 30.2 1.8%
MRNA
Moderna, Inc.
 $96.65B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.13B +4.6% +20.8% 20.0 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
22
% held
36.8%
Net QoQ
+236.1K sh
Top holder
Lynx1 Capital Management…
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Falling
Shares short
20.0K
Days to cover
1.6d
Change
-4.7K sh
View
Short Volume
Short vol %
0%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
915
Value
$3.3K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
41.1%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.2M
Net income (FY)
$-13.5M
EPS diluted
$-3.06
View
Filings
SEC Filings
Latest
DEF 14A
Filed
Sep 18, 2026
This year
7
View
Earnings & Events
Investor Relations
Latest news
Neuphoria Responds to the announc…
Published
Jun 26, 2026
View

Performance

5D 20D 120D MTD YTD
NEUP +0.0% -9.2% -34.7% -4.8% -12.6%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY +1.2% -8.7% -42.8% -5.6% -25.4%
Key facts CIK 1191070 CUSIP 64136E102 Visit website Investor relations